Eli Lilly (LLY) Other Non-Current Liabilities (2009 - 2026)

Eli Lilly (LLY) has 18 years of Other Non-Current Liabilities data on file, last reported at $4.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 78.51% year-over-year to $4.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.1 billion (up 78.51% YoY), and the FY2025 full-year result was $4.0 billion, down 2.24% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.1 billion, up from $4.0 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $6.3 billion in Q3 2025 and bottomed at $1.7 billion in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $2.3 billion (2025), against an average of $2.8 billion.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities slumped 52.3%; it then surged 181.04% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $1.8 billion in 2022, then rose by 22.84% to $2.2 billion in 2023, then jumped by 81.25% to $4.1 billion in 2024, then retreated by 2.24% to $4.0 billion in 2025, then advanced by 2.9% to $4.1 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.1 billion (Q1 2026), $4.0 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.

Peer Comparison